Anacetrapib

DRUG12 trials

Sponsors

Merck Sharp & Dohme LLC, University of Oxford, Cambridge University Hospitals NHS Foundation Trust

Conditions

Atherosclerotic Cardiovascular DiseaseCHD Risk-Equivalent DiseaseCoronary Heart Disease (CHD)DyslipidemiaHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial HypercholesterolemiaHypercholesterolemiaHypercholesterolemia, Familial

Phase 1

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

CompletedNCT00990808

Merck Sharp & Dohme LLCDyslipidemia

Start: 2009-11-30End: 2011-07-31Updated: 2015-06-04

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

CompletedNCT01114490

Merck Sharp & Dohme LLCDyslipidemia

Start: 2010-05-31End: 2010-07-31Updated: 2015-10-14

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

CompletedNCT01122667

Merck Sharp & Dohme LLCDyslipidemia

Start: 2010-06-30End: 2011-06-30Updated: 2015-08-14

Phase 2

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

CompletedNCT00977288

Merck Sharp & Dohme LLCDyslipidemia

Start: 2009-09-30End: 2014-04-30Updated: 2015-05-06

Phase 3

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

CompletedNCT00685776

Merck Sharp & Dohme LLCCHD Risk-Equivalent Disease, Coronary Heart Disease (CHD)

Start: 2008-03-24End: 2017-11-23Updated: 2017-12-11

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Active, not recruitingNCT01252953

University of OxfordAtherosclerotic Cardiovascular Disease

Start: 2011-06-30End: 2037-01-31Updated: 2024-06-25

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

CompletedNCT01524289

Merck Sharp & Dohme LLCHypercholesterolemia, Familial, Hyperlipoproteinemia Type II

Start: 2012-02-03End: 2018-11-13Updated: 2019-10-14

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

CompletedNCT01760460

Merck Sharp & Dohme LLCDyslipidemia

Start: 2013-03-14End: 2015-03-04Updated: 2017-06-01

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

CompletedNCT01824238

Merck Sharp & Dohme LLCHeterozygous Familial Hypercholesterolemia (HeFH)

Start: 2013-05-31End: 2014-05-31Updated: 2016-04-25

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

TerminatedNCT01841684

Merck Sharp & Dohme LLCHomozygous Familial Hypercholesterolemia, Hyperlipoproteinemia Type II

Start: 2013-06-30End: 2014-06-30Updated: 2015-06-01

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

CompletedNCT01860729

Merck Sharp & Dohme LLCHypercholesterolemia

Start: 2013-05-13End: 2015-08-20Updated: 2020-05-29

Unknown Phase

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

CompletedNCT02931188

Cambridge University Hospitals NHS Foundation TrustAtherosclerotic Cardiovascular Disease, Vascular Disease

Start: 2017-01-31End: 2018-05-31Updated: 2024-02-07

Related Papers

Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States

Journal of the American Heart Association2023-09-2623 citations

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

European Heart Journal2021-12-0255 citations

Impact of <i>ADCY9</i> Genotype on Response to Anacetrapib

Circulation2019-07-2334 citations

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

New England Journal of Medicine2017-08-291014 citations

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

Arteriosclerosis Thrombosis and Vascular Biology2017-07-2193 citations

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia

Atherosclerosis2017-03-1016 citations

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.

2016-03-259 citations

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

2015-05-1162 citations

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

2015-03-0375 citations

Abstract 9613: Randomized Evaluation of Anacetrapib Lipid-Modifying Therapy in Patients With HeteroZygous Familial HypercholesterolEmia (REALIZE Study)

Circulation2014-11-25

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

2014-11-0419 citations

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

2010-11-17523 citations

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

2009-10-0162 citations